FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP
666 FIFTH AVENUE, 31ST FLOOR
NEW YORK, NEW YORK 10103-3198
WWW.FULBRIGHT.COM

FACSIMILE TRANSMISSION

_			
n	47	ď	•

February 13, 2003

MATTER NUMBER:

10103726

RECIPIENT(s):	FAX No.:	PHONE No.:	
Examiner Sandra Saucier	703-308-2742		\neg
USPTO, Group 1651			

FAX RECEIVED
FEB 1 4 2003
GROUP 1600

Norman Hanson

USER ID:

NH01030

FLOOR:

PHONE: (212) 318-3168

FAX:

(212) 318-3400

RE:

NIAD 213.1

Number of Pages with Cover Page:

Message:	1	
	•	

CAUTION - CONFIDENTIAL

THE INFORMATION CONTAINED IN THIS FACSIMILE IS CONFIDENTIAL AND MAY ALSO CONTAIN PRIVILEGED ATTORNEY-CLIENT INFORMATION OR WORK PRODUCT. THE INFORMATION IS INTENDED ONLY POR THE USE OF THE INDIVIDUAL OR ENTITY TO WHOM IT IS ADDRESSED. IF YOU ARE NOT THE INTENDED RECIPIENT, OR THE EMPLOYEE OR AGENT RESPONSIBLE TO DELIVER IT TO THE INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT ANY USE. DISSEMINATION, DISTRIBUTION OR COPYING OF THIS COMMUNICATION IS STRICTLY PROHIBITED. IF YOU HAVE RECEIVED THE FACSIMILE IN ERROR, PLEASE IMMEDIATELY NOTIFY US BY TELEPHONE, AND RETURN THE ORIGINAL MESSAGE TO US AT THE ADDRESS ABOVE VIA THE U.S. POSTAL SERVICE, THANK YOU.

IF YOU DO NOT RECEI	IVE ALL OF THE PAGES,	, PLEASE CALL
AT	A	S SOON AS POSSIBLE

TO 0103010103726170 P. 02/04

NIAD 213.1 (10103726)- NDH

VIA FACSIMILE

I hereby certify that this correspondence is being facsimile transmitted to the Commissioner of Patents and Trademarks, Washington, D.C. 20231 on February 13, 2003.

Fulbright & Jaworski LLP.

Laure Olles

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Applicant

Jacobson, et al.

Serial No.

09/836,576

Filed

April 16, 2001

For

METHODS FOR IDENTIFYING REGULATORS OF

PROTEIN-ADVANCED GLYCATION END PRODUCT

(PROTEIN-AGE) FORMATION

Art Unit

1651

Examiner

S. Saucier

February 13 2003

Hon. Commissioner of Patents and Trademarks Washington, D.C. 20231

RESPONSE TO RESTRICTION REQUIREMENT AND AMENDMENT

This is in response to the restriction requirement of February 5. The examiner required restriction between method claims 1-10, and kit claim 11.

Applicants elect Group I, claims 1-10, with traverse.

The examiner argues that the kit of Group II is not required to carry out the assay, and kits have structure not required in the carrying out of the assay.

Applicants respond by noting that the examiner has not pointed to any other use for the kit of claim 11 other than for use in the assay of claims 1-10. With respect to the examiner's point regarding "multiple methods," this is obscure. The relevance to the invention is not seen. In any event, since the claimed subject matter, i.e., claims 1-10, requires both histone H1 and

25262R36.1